This presentation explores the emerging science behind MAG-EPA™, a patented monoglyceride form of EPA, as a next-gen prebiotic with systemic benefits for cellular and mitochondrial function. Developed for high absorption and metabolic activity, MAG-EPA™ has been shown in both clinical and preclinical models to influence gut microbiota composition, short-chain fatty acid profiles, and tissue-level signaling cascades associated with energy metabolism, apoptosis, and immune modulation.
Drawing from peer-reviewed studies and randomized controlled trials, Dr. Samuel Fortin presents data showing how MAG-EPA™ supports:
- Mitochondrial efficiency and cellular energy production
- Regulation of apoptosis pathway
- Reduced vascular signaling and improved tissue homeostasis
- Remodeling of gut microbiota ecosystems linked to metabolic resilience
Attendees will gain insight into the mechanistic links between targeted omega-3 prebiotic intake and healthy aging, mitochondrial health, and immune system balance — all without pharmacological interventions.